Genomic Data Analytics · Healthcare Performance Intelligence
Genomic Data Analytics That Keep Predisposition Separate from Phenotype
Investigate interpreted genomic outputs alongside what is actually expressed over time in biomarkers, history and clinical observations.
See What Vizier Finds in Your DataBring the data you already collect. Keep the systems that produce it.
The buyer problem
More data has made interpretation harder for precision-health clinicians, genomics labs and data leaders.
Genomic reports are frequently static. Their relevance depends on ancestry, evidence quality, phenotype and the question being asked; the genome does not change, but the surrounding evidence does.
The answer is not another isolated dashboard. It is a governed way to evaluate change across time and modalities, preserve what each source can and cannot establish, and make the underlying evidence available for review.
Where interpretation breaks
- Risk outputs are detached from phenotype
- Variant evidence changes after report delivery
- Ancestry limitations are omitted
- Predisposition is communicated as destiny
Data landscape
The signals involved
The job is not to force unlike data into one score. It is to preserve provenance, time, context and uncertainty while making the relationships investigable.
Interpreted variants
Reviewed variant and pharmacogenomic outputs with source and classification date.
Risk models
Polygenic or other risk outputs with population and model context.
Phenotype
Diagnoses, family history, biomarkers, medications and observed traits.
Longitudinal evidence
New observations that support, contradict or leave a genetic hypothesis unresolved.
The intelligence layer
What Vizier adds
Genotype–phenotype review
Place predisposition beside observed phenotype without collapsing the distinction.
Evidence-date awareness
Show when classification or source evidence requires re-review.
Clinical-context filtering
Prioritise findings relevant to the authorised question and available phenotype.
Uncertainty communication
Expose limitations rather than imply deterministic outcomes.
Interpretation discipline
Evidence before certainty
Vizier should make complex data easier to investigate without making the evidence stronger than it is. A temporal relationship is not automatically causal. A genetic association is not a diagnosis. Movement in a surrogate biomarker is not necessarily a clinical outcome.
Findings should retain source, timing, reference context and confidence. Where modalities disagree, data is missing, or follow-up is too short, the useful answer is often that the evidence is insufficient.
The distinctions that matter
- Association is not causality; timing and confounding still matter.
- Genetic predisposition is not the same as expressed phenotype.
- Biomarker movement is not automatically a clinical outcome.
- A biological-age estimate is model output, not a lifespan prediction.
Clear product boundary
What Vizier does—and does not—replace
Vizier does not sequence DNA, process FASTQ/BAM files, call variants or independently classify pathogenicity. It analyses outputs supplied by qualified genomics systems.
Vizier consumes authorised outputs from the systems you choose. Source access, format, identity matching, governance, hosting and clinical review responsibilities are confirmed during discovery.
Vizier is not
- A sequencing or FASTQ/BAM/VCF processing pipeline
- A laboratory, EHR, scheduling, billing or CRM system
- A diagnostic device or autonomous clinical decision-maker
- A claim that an intervention caused a later change
Workflow
From fragmented outputs to a reviewable investigation
01
Inventory authorised sources, identifiers, time semantics and decision questions.
02
Validate units, mappings, provenance, missingness and clinically relevant comparison periods.
03
Configure longitudinal and cross-signal investigations around the organisation's reviewed definitions.
04
Return findings with evidence, uncertainty and a traceable path back to source data.
Questions buyers ask
Frequently asked questions
What is genomic data analytics?
Genomic Data Analytics is the governed analysis of relevant health data for longitudinal and cross-signal questions. For Vizier, that means analysing authorised outputs while retaining provenance, time and uncertainty.
Does Vizier replace our existing clinical or diagnostic systems?
Vizier does not sequence DNA, process FASTQ/BAM files, call variants or independently classify pathogenicity. It analyses outputs supplied by qualified genomics systems.
Can Vizier prove that an intervention caused a change?
Not from timing alone. Vizier can align observations to an intervention, show competing explanations and describe the strength of evidence. Causal claims require an appropriate design and expert review.
How does implementation start?
With one decision question and a source inventory. Vizier validates access, identifiers, units, time semantics, governance and the review workflow before a capability is represented as production-ready.
See genomic data analytics across the data you already collect.
Bring the data you already collect. See what Vizier finds across it.
Start with the data you already have. Connect your EHR when you’re ready.